

Published in final edited form as:

*Nat Immunol.* 2017 January ; 18(1): 74–85. doi:10.1038/ni.3632.

## Trans-presentation of interleukin-6 by dendritic cells is required for priming pathogenic T<sub>H</sub>17 cells

Sylvia Heink<sup>1,¶</sup>, Nir Yogev<sup>2,3,¶</sup>, Christoph Garbers<sup>4</sup>, Marina Herwerth<sup>1,5</sup>, Lilian Aly<sup>1</sup>, Christiane Gasperi<sup>1</sup>, Veronika Husterer<sup>1</sup>, Andrew L. Croxford<sup>2</sup>, Katja Möller-Hackbarth<sup>4</sup>, Harald S. Bartsch<sup>6</sup>, Karl Sotlar<sup>6</sup>, Stefan Krebs<sup>7</sup>, Tommy Regen<sup>2</sup>, Helmut Blum<sup>7</sup>, Bernhard Hemmer<sup>1,8</sup>, Thomas Misgeld<sup>5,8</sup>, Thomas F. Wunderlich<sup>9</sup>, Juan Hidalgo<sup>10</sup>, Mohamed Oukka<sup>11,12</sup>, Stefan Rose-John<sup>4</sup>, Marc Schmidt-Supprian<sup>13</sup>, Ari Waisman<sup>2,§</sup>, and Thomas Korn<sup>1,8,§,\*</sup>

<sup>1</sup>Klinikum rechts der Isar, Dept. of Neurology, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany

<sup>2</sup>Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg University, Obere Zahlbacher Str. 67, 55131 Mainz, Germany

<sup>4</sup>Institute of Biochemistry, Kiel University, Olshausenstrasse 40, 24098 Kiel, Germany

<sup>5</sup>Institute of Neuronal Cell Biology, Technical University of Munich, Germany

<sup>6</sup>Institute of Pathology, Medical School, Ludwig-Maximilians-University, 80337 Munich, Germany

<sup>7</sup>Gene Centre, Lafuga, Ludwig-Maximilians-University, Feodor-Lynen-Strasse 25, 81377 Munich, Germany

<sup>8</sup>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

<sup>9</sup>Max Planck Institute for Metabolism Research, Gleueler Str. 50, 50931 Cologne, Germany

<sup>10</sup>Department of Cellular Biology, Physiology, and Immunology, Autonomous University of Barcelona, Barcelona 08193, Spain

<sup>11</sup>Department of Immunology, University of Washington, Seattle, WA 98101

<sup>12</sup>Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA 98101

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Correspondence: Thomas Korn [thomas.korn@tum.de](mailto:thomas.korn@tum.de), Phone: ++49-89-4140-5617, Fax: ++49-89-4140-4675.

<sup>3</sup>Current address: Department of Neurology, University Medical Center of the Johannes Gutenberg University, Langenbeck Str. 1, 55131 Mainz, Germany

¶Shared first authorship

§Shared senior authorship

### Author contributions

S.H. designed, performed and analyzed most experiments and drafted the manuscript. N.Y. performed and analyzed key *in vivo* experiments, C. Garbers, M.H., L.A., V.H., A.L.C., K.M.-H., and T.R. performed or contributed to specific experiments. C. Gasperi performed bioinformatic analysis. H.S.B. and K.S. performed and analyzed nanostring experiments. S.K. and H.B. performed and analyzed RNAseq experiments. T.W., B.H., T.M., J.H., M.O., S.R.-J., M.S.-S. provided reagents, advice, design, and supervision to experiments. A.W. supervised experiments, analyzed data, and wrote the manuscript. T.K. conceptualized the study, designed and supervised the experiments, analyzed data, and wrote the manuscript.

The authors declare no competing financial interest.

<sup>13</sup>Dept. of Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany

## Abstract

The cellular sources of interleukin-6 (IL-6) that are relevant for the differentiation of T<sub>H</sub>17 cells remain unclear. Here, we used a novel strategy of IL-6 conditional deletion of distinct IL-6-producing cell types to show that Sirpα<sup>+</sup> dendritic cells (DC) were essential for the generation of pathogenic T<sub>H</sub>17 cells. During the process of cognate interaction, Sirpα<sup>+</sup> DCs trans-presented IL-6 to T cells using their own IL-6Rα. While ambient IL-6 was sufficient to suppress the induction of the transcription factor Foxp3 in T cells, IL-6 trans-presentation by DC-bound IL-6Rα (here defined as IL-6 cluster signaling) was required to prevent premature induction of IFN-γ in T cells and to generate pathogenic T<sub>H</sub>17 cells *in vivo*. These findings will guide therapeutic approaches for T<sub>H</sub>17-mediated autoimmune diseases.

---

During antigen-specific priming, CD4<sup>+</sup> T helper (T<sub>H</sub>) cells differentiate into distinct subsets characterized by specific master transcription factors and signature cytokines. The differentiation process is controlled by various cytokines present in the micro-environment, in which CD4<sup>+</sup> T cells cognately interact with antigen presenting cells. Because T cell receptor (TCR) stimulation in the presence of the ubiquitously expressed cytokine TGF-β results in induction of the transcription factor Foxp3, productive effector T cell responses require efficient ways to suppress Foxp3 induction in T cells during priming. Although interleukin 27 (IL-27) has additional regulatory functions 1, IL-27 and IL-4 are strong inhibitors of Foxp3 induction during the development of T<sub>H</sub>1 cells and T<sub>H</sub>2 cells, respectively 2–4. During T<sub>H</sub>17 cell development, IL-6 prevents the transcription of Foxp3 and at the same time induces IL-17 5,6. However, it is unclear whether these functions of IL-6 are connected with each other or are independent events.

T<sub>H</sub>17 cells are categorized into pathogenic vs non-pathogenic depending on whether or not they have sensed IL-23 7,8. However, single cell analysis of T<sub>H</sub>17 cells isolated from the inflamed CNS reveals that individual T<sub>H</sub>17 cells can exhibit a non-pathogenic gene signature including transcription factors (*Eomes*, *Irf8*, *c-Maf*), cytokines (*Il24*, *Il9*) and surface receptors (*Cxcr6* and *Cd96*) although they express *Il23r* 9. Thus, the decision of whether a T<sub>H</sub>17 cell will become pathogenic can be taken independently of IL-23 and might be installed early during priming.

Because IL-6 is the dominant factor to initiate the transcriptional program of T<sub>H</sub>17 cells, we speculated that intrinsic properties of IL-6 might be a major determinant of priming pathogenic T cells. In order to signal into target cells, IL-6 first binds to the IL-6Rα subunit. This complex then associates with gp130, the signaling subunit of the IL-6 receptor, resulting in a heterohexameric signaling complex (IL-6, IL-6Rα, gp130 in a 2:2:2 stoichiometry) that triggers productive IL-6 signaling into the target cell 10,11. In addition to the membrane form, IL-6Rα can be shed and bind IL-6 as a soluble receptor. The IL-6-sIL-6Rα soluble complex associates with gp130 and initiates IL-6 signaling in gp130<sup>+</sup> cells. This type of IL-6 signaling is termed IL-6 trans-signaling 12,13. In contrast to classic IL-6

signaling, IL-6 trans-signaling can be blocked by soluble gp130 which acts as a decoy receptor for the soluble IL-6-IL-6Ra complex 14.

Here, in order to investigate whether the cellular source of IL-6 was a determinant of T<sub>H</sub>17 cell fate, we developed a novel IL-6 reporter strategy that allowed for the IL-6 conditional deletion of distinct cell types. We show that a subset of CD11b<sup>+</sup> DCs that are Sirpα<sup>+</sup> are indispensable for priming of myelin peptide specific encephalitogenic T cells. Our data indicate that CD11b<sup>+</sup>Sirpα<sup>+</sup> DCs are able to trans-present IL-6 through a complex containing DC-expressed IL-6Rα bound to IL-6 that can interact with gp130 expressed on T cells. We define this mode of IL-6 signaling as ‘cluster signaling’ and propose that imprinting of encephalitogenic properties in effector T cells is dependent on IL-6 cluster signaling, while classic IL-6 signaling through its membrane bound receptor complex is sufficient to suppress the TGF-β-induced expression of Foxp3, but fails to prime pathogenic T<sub>H</sub>17 cells.

## Results

### DCs are the relevant source of IL-6 for priming pathogenic T<sub>H</sub>17 cells

Because IL-6 is produced by different hematopoietic and non-hematopoietic cells, we sought to define the relevant cellular source of IL-6 for the differentiation of pathogenic T<sub>H</sub>17 cells. We generated an IL-6 reporter knock-in allele (*Il6<sup>RD</sup>*), in which IL-6 expression is reported by cerulean and Thy1.1 expression (Supplementary Fig. 1). In addition, the reporter contains a floxed stop cassette that allows a cell type-specific expression of the reporter cassette depending on the Cre driver used in various mouse strains. First, we crossed *Il6<sup>RD/wt</sup>* mice with a CMV-Cre deleter strain to allow for unrestricted expression of the IL-6 reporter cassette and immunized these mice with MOG<sub>35-55</sub> in CFA. On day 7 after immunization, Thy1.1 (IL-6) was exclusively produced by CD45<sup>+</sup> hematopoietic cells in draining lymph node cells and spleen of CMV-Cre x *Il6<sup>RD/wt</sup>* mice. CD11c<sup>+</sup> cells contained the largest frequencies of Thy1.1 (IL-6)<sup>+</sup> cells (Fig. 1a). Subgroup analysis revealed that Thy1.1 (IL-6) expression was restricted to CD11b<sup>+</sup>Sirpα<sup>+</sup>CD103<sup>-</sup>SiglecH<sup>-</sup> DCs (Supplementary Fig. 2). In draining lymph nodes, some DCs were Thy1.1<sup>+</sup> already on the first day after immunization with MOG<sub>35-55</sub> in CFA. The subset of Thy1.1<sup>+</sup> DCs was maintained at least through day 6 after immunization (Fig. 1b). At the peak of EAE (day 16 post immunization), Thy1.1<sup>+</sup> cells in the CNS were mainly CD45<sup>+</sup>CD11b<sup>+</sup> myeloid cells (Fig. 1c). Nevertheless, and in contrast to the peripheral immune compartment, a substantial fraction of IL-6 in the CNS appeared to be produced by non-hematopoietic cells. Importantly, specific ablation of IL-6-producing DCs in CD11c-Cre x *Il6<sup>RD/wt</sup>* mice using an anti-Thy1.1 antibody (Supplementary Fig. 2) resulted in the priming of MOG<sub>35-55</sub>-specific T cells with reduced IL-17 and increased IFN-γ production (Fig. 1d, Supplementary Fig. 3) and abrogated the development of EAE (Fig. 1e). These data suggested that either IL-6 production by DCs or the physical presence of IL-6-producing DCs were required for the induction of EAE. In order to discriminate between these possibilities, we conditionally deleted *Il6* in DCs using CD11c-Cre and *Il6<sup>fllox</sup>* alleles. Loss of *Il6* in dendritic cells in CD11c-Cre x *Il6<sup>fllox/fllox</sup>* mice, herein called *Il6<sup>ADC</sup>*, resulted in complete resistance to EAE, despite the continued presence of CD11b<sup>+</sup>Sirpα<sup>+</sup> DCs in these mice (Fig. 1f). Indeed, *Il6<sup>ADC</sup>* mice phenocopied *Il6<sup>-/-</sup>* mice

in their resistance to EAE. Apart from DCs, some Thy1.1 (IL-6) was expressed by T cells, B cells and macrophages (Fig. 1a). Conditional deletion of *I16* in these cells modulated disease severity, but did not abrogate EAE development (Supplementary Fig. 4). Thus, DC-derived IL-6 is essential for priming pathogenic T cell responses in EAE.

### DC derived IL-6 is sensed by interacting T cells in a specific manner

Our data would be consistent with the idea that DC-derived IL-6 acted back on DCs in an autocrine manner to boost their ability to prime pathogenic T<sub>H</sub>17 cells. However, no major differences in the induction of *I11b*, *I112* or *I123* were observed between wild-type and IL-6R $\alpha$ -deficient BMDCs, which cannot respond to soluble IL-6, upon exposure to exogenous IL-6 (Supplementary Fig. 5). Thus, we explored alternative modes of action of DC-derived IL-6 during cognate interaction with T cells. Naive (Foxp3<sup>-</sup>) CD4<sup>+</sup> T cells from 2D2 x *Foxp3gfp*.KI mice, which express a MOG<sub>35-55</sub>-specific transgenic TCR and in which Foxp3 expression is reported by GFP, were transferred into *I16<sup>flox/flox</sup>* control, *I16<sup>-/-</sup>* or *I16<sup>ADC</sup>* mice followed by subcutaneous immunization with MOG<sub>35-55</sub> in CFA. As previously reported 15, priming of transgenic T cells in an IL-6-deficient environment in the *I16<sup>-/-</sup>* mice resulted in the conversion of about 20% 2D2 T cells into GFP (Foxp3)<sup>+</sup> Treg cells (Fig. 2a). In contrast, we did not observe conversion of GFP<sup>-</sup> 2D2 T cells into GFP<sup>+</sup> 2D2 T cells during priming of naive 2D2 T cells in the *I16<sup>ADC</sup>* mice, indicating that IL-6 from sources other than DCs was sufficient to suppress the conversion of conventional T cells into Foxp3<sup>+</sup> Treg cells during antigen specific priming. Indeed, the systemic amount of IL-6 measured in the serum after subcutaneous immunization with MOG<sub>35-55</sub> peptide in CFA was similar in *I16<sup>flox/flox</sup>* and *I16<sup>ADC</sup>* animals (Supplementary Fig. 6).

Although the emergence of Foxp3<sup>+</sup> Treg cells was equally suppressed in *I16<sup>ADC</sup>* as in IL-6-sufficient (*I16<sup>flox/flox</sup>*) mice, *I16<sup>flox/flox</sup>* mice developed EAE following immunization with MOG<sub>35-55</sub> in CFA, while *I16<sup>ADC</sup>* mice did not (Fig. 1f). Thus, to search for effector T cell-intrinsic features that would explain the inability of *I16<sup>ADC</sup>* primed T cells to induce EAE, we performed RNA sequencing analysis of GFP (Foxp3)<sup>-</sup> 2D2 T cells that were re-isolated from the draining lymph nodes of *I16<sup>flox/flox</sup>*, *I16<sup>-/-</sup>* or *I16<sup>ADC</sup>* mice on day 6 after immunization with MOG<sub>35-55</sub> in CFA. The set of genes differentially expressed in 2D2 T cells isolated from *I16<sup>-/-</sup>* vs *I16<sup>flox/flox</sup>* control mice was defined as IL-6 target genes (Supplementary Table 1). Within this set, we identified those genes enriched in 2D2 T cells primed in *I16<sup>ADC</sup>* vs *I16<sup>flox/flox</sup>* mice (Fig. 2b, Supplementary Tables 2 and 3) and analyzed upstream pathways compatible with this enrichment by ingenuity pathway analysis (Supplementary Fig. 6). We found that differential activation of Stat3 was the major predictor of the distinct gene enrichment profiles of 2D2 T cells primed in *I16<sup>ADC</sup>* vs *I16<sup>flox/flox</sup>* (Supplementary Fig. 6). Moreover, when we directly tested a published Stat3 dependent gene set 16, Stat3 target genes were enriched in 2D2 T cells primed in *I16<sup>flox/flox</sup>* over *I16<sup>ADC</sup>* mice (Supplementary Fig. 6 and Supplementary Table 4). Thus, we tested the activation of Stat3 in T cells in *I16<sup>flox/flox</sup>*, *I16<sup>-/-</sup>* or *I16<sup>ADC</sup>* mice. Naive 2D2 T cells were co-cultured with *I16<sup>flox/flox</sup>*, *I16<sup>-/-</sup>* or *I16<sup>ADC</sup>* splenocytes in the presence of cognate antigen (MOG<sub>35-55</sub>). After LPS stimulation, Stat3 activation was negligible in T cells cultured with *I16<sup>-/-</sup>* APCs. Stat3 activation was delayed in T cells primed with *I16<sup>ADC</sup>* APCs compared to wild-type APC-primed T cells (Fig. 2c) despite similar amounts of soluble IL-6 in the

supernatant of wild-type APC-T cell and *Il6<sup>ADC</sup>* APC-T cell co-cultures (Fig. 2d). Thus, IL-6 induced an early and robust activation of Stat3 in antigen-specific 2D2 T cells only when provided by DCs.

In addition, because the *in vivo* priming of 2D2 T cells in *Il6<sup>ADC</sup>* mice resulted in a highly efficient suppression of Foxp3 induction (Fig. 2a), we investigated whether activation of Stat3 had differential effects on the IL-6-mediated suppression of Foxp3 expression and the induction of effector properties in conventional T cells. Naive CD44<sup>+</sup>CD25<sup>-</sup>CD4<sup>+</sup> T cells from *Stat3<sup>flox/flox</sup>* control mice or CD4-Cre x *Stat3<sup>flox/flox</sup>* mice (*Stat3<sup>ΔT</sup>*) were activated *in vitro* with anti-CD3 and anti-CD28 in the presence of TGF-β without and with IL-6 followed by assessment of Foxp3 induction and effector cytokines. As expected, Stat3 was indispensable for the induction of IL-17 (Fig. 2e). However, Stat3 deficient T cells produced high amounts of IFN-γ when differentiated under T<sub>H</sub>17 conditions (Fig. 2e, f). The TGF-β-induced expression of Foxp3 was (at least in part) suppressed by IL-6 in Stat3 deficient T cells (Fig. 2e, f), indicating that lack of Stat3 in T cells resulted in a T<sub>H</sub>1-like phenotype under T<sub>H</sub>17 differentiation conditions. In summary, these data suggest that T cells can distinguish between DC-derived IL-6 and IL-6 from other sources due to different Stat3 activation kinetics translating into different T cell phenotypes.

### IL-6 cluster signaling is an efficient signaling mode

Besides classic IL-6 signaling through soluble IL-6 (sIL-6) binding to its membrane-bound receptor, soluble IL-6Rα-IL-6 complexes engage gp130 on target cells that lack IL-6Rα, a process called IL-6 trans-signaling 13. We tested whether during a cognate DC-T cell encounter, DC-bound IL-6Rα trans-presents DC-derived IL-6 to T cells through a distinct IL-6 trans-presentation process, which requires the clustering of donating and receiving cell - hence named here IL-6 cluster signaling. First, we established the functionality of IL-6 cluster signaling by retrovirally expressing either IL-6Rα (without eGFP) or gp130-eGFP in Ba/F3 cells, an IL-3-dependent murine pro-B-cell line that lacks both endogenous IL-6Rα and gp130 expression 17,18, followed by testing their proliferative response to IL-6 signaling (Fig. 3a). While in separate cultures, Ba/F3-IL-6Rα cells, which lacked gp130, did not proliferate in response to either sIL-6 or a sIL-6-soluble IL-6Rα complex (hereafter hyper-IL-6 19) (Fig. 3a), Ba/F3-gp130-eGFP cells, which lacked IL-6Rα, proliferated in response to hyper-IL-6, but not sIL-6 (Fig. 3a), suggesting that hyper-IL-6 formed a functional signaling complex with membrane bound gp130-eGFP in Ba/F3-gp130-eGFP cells. Notably, when Ba/F3-gp130-eGFP cells were co-cultured with Ba/F3-IL-6Rα cells, sIL-6 alone induced the proliferation of Ba/F3-gp130-eGFP cells (Fig. 3b, c), suggesting that Ba/F3-IL-6Rα cells trans-presented IL-6 to Ba/F3-gp130-eGFP cells, inducing the proliferation of the latter cells. This IL-6 cluster signaling requires the clustering of Ba/F3-IL-6Rα cells and Ba/F3-gp130-eGFP cells in the same co-culture. Exogenous IL-6Rα Abs, but not soluble gp130 (sgp130-Fc), a strong inhibitor of IL-6 trans-signaling by hyper-IL-6, neutralized IL-6 cluster signaling (Fig. 3b), indicating that IL-6 trans-signaling and IL-6 cluster signaling are functionally different. Together, these results suggest that IL-6 bound to IL-6Rα on the surface of IL-6Rα-expressing cells signals through membrane-bound gp130 in cells that do not express IL-6Rα when both cell types are in physical proximity.

## DCs present IL-6 *in trans* and induce IL-6 cluster signaling

Next, we tested the ability of DCs to present IL-6 *in trans* during a cognate interaction with T cells (Supplementary Fig. 7). Naive (CD4<sup>+</sup>CD44<sup>-</sup>GFP (Foxp3)<sup>-</sup>) 2D2 T cells were co-cultured with BMDCs in the presence of cognate antigen (MOG<sub>35-55</sub>) and LPS to induce IL-6 production in BMDCs. GFP (Foxp3)<sup>-</sup> effector 2D2 T cells showed robust Stat3 activation assessed by flow cytometry when they were co-cultured with wild-type BMDCs, but not after culture with *Il6ra*<sup>-/-</sup> BMDCs, although the amount of soluble IL-6 produced by wild-type and *Il6ra*<sup>-/-</sup> BMDCs was similar (Fig. 4a, b). To test if IL-6 cluster signaling occurred during cognate DC-T cell interactions, we co-cultured wild-type BMDCs with naive T cells isolated either from wild-type or CD4-Cre x *Il6ra*<sup>flx/flx</sup> (*Il6ra*<sup>ΔT</sup>) mice, and used *Staphylococcal* enterotoxin B (SEB), a superantigen that activates TCR-Vβ8<sup>+</sup> T cells in an MHC class II dependent manner. TCR-Vβ8<sup>+</sup> T cells exhibited an increased p-Stat3 signal compared to TCR-Vβ8<sup>-</sup> T cells present in the same culture (Fig. 4c). In addition, Stat3 activation occurred in both wild-type and *Il6ra*<sup>ΔT</sup> TCR-Vβ8<sup>+</sup> T cells. In contrast, exogenous soluble IL-6 induced p-Stat3 in wild-type, but not by *Il6ra*<sup>ΔT</sup> T cells (Fig. 4c). In addition, when MOG<sub>35-55</sub>-specific transgenic 2D2 T cells and OVA<sub>323-339</sub>-specific transgenic OT II T cells were co-cultured with wild-type BMDCs in a triple culture, early Stat3 phosphorylation was exclusively observed in T cells whose cognate antigen was present in the culture but not in co-cultured T cells with irrelevant specificity (Fig. 4d, e), suggesting that IL-6 cluster signaling did not result in bystander activation of T cells that did not interact with DCs in a cognate manner.

In order to further characterize IL-6 cluster signaling during a DC-T cell interaction, we used a variety of IL-6 blocking reagents at the time of LPS activation of BMDCs co-cultured with 2D2 T cells in the presence of MOG<sub>35-55</sub>. The monoclonal antibody MR16-1, which binds IL-6Rα, completely abolished the p-Stat3 signal in 2D2 T cells (Fig. 4f). In contrast, sgp130-Fc did not inhibit p-Stat3 in 2D2 T cells (Fig. 4f), indicating that sgp130-Fc cannot engage the membrane bound IL-6-IL-6Rα complex interacting with gp130 *in trans*. In addition, antibodies to IL-6, and in particular mAb #8, a monoclonal IL-6 antibody that binds the interaction site between IL-6 and IL-6Rα, failed to block Stat3 activation in T cells in response to LPS activated co-cultured BMDCs (Fig. 4f). Because IL-6 bound in a complex with IL-6Rα would be less easily neutralized by IL-6 antibodies, we tested whether IL-6 was loaded onto the IL-6Rα in the intracellular compartment and transported to the cell membrane of DCs as a complex. We incubated equal mixtures of *Il6ra*<sup>-/-</sup> and wild-type BMDCs or *Il6ra*<sup>-/-</sup> and *Il6*<sup>-/-</sup> BMDCs with naive (CD44<sup>-</sup>GFP (Foxp3)<sup>-</sup>) 2D2 T cells in the presence of MOG<sub>35-55</sub> and stimulated the cultures with LPS. Within 120 min after LPS stimulation, *Il6ra*<sup>-/-</sup> + wild-type BMDCs elicited Stat3 activation in GFP (Foxp3)<sup>-</sup> effector T cells comparable to wild-type BMDCs alone, while *Il6ra*<sup>-/-</sup> + *Il6*<sup>-/-</sup> BMDCs failed to induce p-STAT3, similar to *Il6ra*<sup>-/-</sup> BMDCs alone (Fig. 4g), indicating that *Il6*<sup>-/-</sup> BMDCs, which express IL-6Rα, do not pick up ambient IL-6 supplied by *Il6ra*<sup>-/-</sup> BMDCs and do not *trans*-present ambient IL-6 to T cells. Notably, there was no clustered IL-6 feedback Stat3 signal into any of the BMDCs present in the co-cultures but only a smoldering Stat3 activation in BMDCs beyond 120 min of LPS stimulation (Fig. 4h). The late p-Stat3 activation in BMDCs was higher in the *Il6ra*<sup>-/-</sup> + wild-type BMDC co-cultures than in the *Il6ra*<sup>-/-</sup> + *Il6*<sup>-/-</sup> BMDC co-cultures (Fig. 4h), suggesting that higher amounts of soluble IL-6 in the *Il6ra*<sup>-/-</sup> +

wild-type BMDC co-cultures (data not shown) were responsible for classic IL-6 signaling into BMDCs. Taken together, DCs load IL-6 onto IL-6R $\alpha$  in their intracellular compartment and use the IL-6-IL-6R $\alpha$  complex to perform IL-6 cluster signaling when cognately interacting with T cells. IL-6 cluster signaling then leads to the targeted activation of Stat3 in antigen specific T cells but not in bystander T cells.

### IL-6 and IL-6R $\alpha$ co-localize in DCs

Next, we used confocal microscopy to visualize IL-6-IL-6R $\alpha$  complexes in BMDCs that interacted with 2D2 T cells in a cognate manner. BMDCs were co-cultured with 2D2 T cells in the presence of MOG<sub>35-55</sub> and stimulated with LPS in the absence of exogenous IL-6. We detected "clustered" IL-6 on the surface of LPS-stimulated BMDCs interacting with 2D2 T cells, with some IL-6 locating at the BMDC-T cell interaction interface (Fig. 5a). To test whether IL-6 and IL-6R $\alpha$  interact on the surface of BMDCs, we performed a proximity ligation assay (PLA) 21. IL-6 deficient, IL-6R $\alpha$  deficient, or wild-type BMDCs were co-cultured with 2D2 T cells in the presence of MOG<sub>35-55</sub> and stimulated with LPS. IL-6 and IL-6R $\alpha$  were simultaneously labeled by antibodies followed by a proximity ligation assay to visualize IL-6-IL-6R $\alpha$  complexes. Positive PLA signals indicating colocalisation of IL-6 and IL-6R $\alpha$  at a distance of less than 40 nm were detected in wild-type BMDC-T cell co-cultures (Fig. 5b) while we observed only few PLA signals in *Il6*<sup>-/-</sup> or *Il6ra*<sup>-/-</sup> BMDC-T cell co-cultures (Fig. 5b, c), suggesting that the background by unspecific PLA amplification reactions was low. Co-localization of IL-6 and IL-6R $\alpha$  occurred in the cytoplasm and at the membrane surface of wild-type BMDCs, with some signal localized at the DC-T cell interaction zone (see xz-projections in Fig. 5b). Thus, DC-associated IL-6-IL-6R $\alpha$  complexes can be visualized in DCs.

### IL-6 cluster signaling during antigen-specific T cell priming *in vivo*

Next, we analyzed whether lack of DC-mediated IL-6 cluster signaling explained the lack of EAE development in *Il6*<sup>ADC</sup> mice. CD11b<sup>+</sup> DCs isolated from the draining lymph nodes of MOG<sub>35-55</sub>-CFA-immunized wild-type mice showed surface and intracellular expression of IL-6R $\alpha$  (Fig. 6a and Supplementary Fig. 7). In MOG<sub>35-55</sub>-CFA-immunized CD11c-Cre x *Il6*<sup>RD/wt</sup> mice, the surface expression of IL-6R $\alpha$  in Thy1.1<sup>+</sup> DCs isolated from the draining lymph nodes was higher than in Thy1.1<sup>-</sup> DCs (Fig. 6b), indicating that DCs that expressed IL-6R $\alpha$  and IL-6 simultaneously can be detected in the draining lymph nodes of immunized mice. In order to investigate the requirement for DC mediated IL-6 cluster signaling in the priming of pathogenic T cells *in vivo*, we immunized CD11c-Cre x *Il6ra*<sup>flox/flox</sup> mice (termed *Il6ra*<sup>ADC</sup>), which lack IL-6R $\alpha$  specifically in DCs, and are thus unable to *trans*-present IL-6 during antigen specific priming, with MOG<sub>35-55</sub> in CFA. Compared to *Il6ra*<sup>flox/flox</sup> control mice, *Il6ra*<sup>ADC</sup> mice were resistant to EAE (Fig. 6c). Thus, IL-6 cluster signaling is required to promote the differentiation of pathogenic T cells during antigen-specific priming in a DC proximal manner.

*In vivo*, sorted naive (CD44<sup>+</sup>GFP (Foxp3)<sup>-</sup>) 2D2 T cells, which had been transferred into congenic CD45.1 host mice followed by immunization with MOG<sub>35-55</sub> in CFA, showed a down-regulation of the surface expression of IL-6R $\alpha$  in the draining lymph nodes as of day 1 after immunization through at least day 5 when engaged in an antigen specific encounter

as defined by upregulation of CD69 or CD25, respectively (Fig. 6d). In addition, sgp130-Fc, which blocks IL-6 trans-signaling<sup>22</sup>, did not ameliorate EAE in sgp130-Fc transgenic mice as compared to wild-type control animals (Supplementary Fig. 8), indicating that soluble IL-6-IL-6R $\alpha$  complexes are irrelevant in EAE. We next tested whether IL-6R $\alpha$ -deficient T cells could respond to IL-6 cluster signaling by DCs and become pathogenic effector T cells by using T cell conditional IL-6R $\alpha$ -deficient mice (*Il6ra*<sup>ΔT</sup>). We found higher frequencies of Foxp3<sup>+</sup> Treg cells in the draining lymph node CD4<sup>+</sup> T cell compartment of *Il6ra*<sup>ΔT</sup> mice immunized with MOG<sub>35-55</sub> in CFA compared to *Il6ra*<sup>fllox/fllox</sup> control animals while MOG<sub>35-55</sub> immunized *Il6ra*<sup>ADC</sup> mice harbored similar Foxp3<sup>+</sup> Treg cell frequencies as *Il6ra*<sup>fllox/fllox</sup> control mice (Fig. 6e), consistent with the observation that ambient IL-6, and thus classic IL-6 signaling, significantly contributes to suppressing the induction of Foxp3<sup>+</sup> Treg cells from conventional T cells in a polyclonal repertoire. Depletion of Treg cells with an anti-CD25 antibody prior to MOG<sub>35-55</sub>-CFA immunization in *Il6ra*<sup>ΔT</sup> mice lead to an increase in the severity of EAE compared to non-Treg cell depleted *Il6ra*<sup>ΔT</sup> mice (Fig. 6f and Supplementary Fig. 9), indicating that *Il6ra*<sup>ΔT</sup> T<sub>H</sub>17 cells could be primed to become pathogenic.

Pathogenic T<sub>H</sub>17 cells can be differentiated with IL-21 *in vivo*, in the absence of IL-6<sup>15,23</sup>. To evaluate the contribution of IL-21 in the pathogenic priming of T cells in *Il6ra*<sup>ΔT</sup> mice, we adoptively transferred naive polyclonal CD4<sup>+</sup> T cells from *Il21r*<sup>-/-</sup> *Il6ra*<sup>ΔT</sup> mice, in which T cells are deficient in the expression of both IL-6R $\alpha$  and IL-21R, into *Rag1*<sup>-/-</sup> host mice, followed by subcutaneous immunization with MOG<sub>35-55</sub> in CFA. *Rag1*<sup>-/-</sup> mice transferred with *Il21r*<sup>-/-</sup> *Il6ra*<sup>ΔT</sup> T cells mounted a T<sub>H</sub>17 response in response to MOG<sub>35-55</sub> immunization and developed EAE (Supplementary Fig. 10). Thus, T cells lacking IL-21 responsiveness and IL-6R $\alpha$  expression that mediates classic IL-6 signaling can still become pathogenic T<sub>H</sub>17 cells.

### Pathogenic T<sub>H</sub>17 cells are dependent on IL-6 cluster signaling

*Il6*<sup>-/-</sup> mice develop an exaggerated Treg cell response upon antigen specific priming with adjuvant 15. Because *Il6*<sup>ADC</sup> mice show normal Foxp3<sup>+</sup> Treg responses, but do not develop EAE we tested whether effector T cell response in *Il6*<sup>ADC</sup> mice were intrinsically inefficient. *Il6*<sup>fllox/fllox</sup> control mice, *Il6*<sup>-/-</sup> and *Il6*<sup>ADC</sup> mice were sensitized with MOG<sub>35-55</sub> in CFA and CD4<sup>+</sup>Foxp3<sup>-</sup> T cells were isolated from draining lymph nodes for transcriptome analysis. Because EAE is essentially a T<sub>H</sub>17 cell mediated model of CNS autoimmunity, we further tested a transcriptional module previously associated with “non-pathogenic” T<sub>H</sub>17 cells<sup>8</sup> in Foxp3<sup>-</sup> T cells primed in the *Il6*<sup>ADC</sup> mice. Gene set enrichment analysis indicated that conventional Foxp3<sup>-</sup> T cells primed in *Il6*<sup>ADC</sup> mice had a significantly higher expression of *Il6st* (gp130), *Cd96*, and *Eomes* as compared to effector T cells primed in a *Il6*<sup>fllox/fllox</sup> control environment (Fig. 7a, b). Notably, CD40L<sup>+</sup>Foxp3<sup>-</sup> T cells primed in the *Il6*<sup>ADC</sup> mice and re-stimulated with MOG<sub>35-55</sub> *in vitro* exhibited significantly higher fractions of IFN- $\gamma$  single producers compared to CD40L<sup>+</sup> effector T cells primed in *Il6*<sup>fllox/fllox</sup> control mice (Fig. 7c), indicating that naïve T cells primed by IL-6 deficient DCs differentiated preferentially into CD96<sup>+</sup>IFN- $\gamma$ <sup>+</sup> T cells, which were incapable of inducing EAE.



*In vitro*, hyper-IL-6 suppressed the upregulation of CD96 in IL-6R $\alpha$ -deficient T cells during T<sub>H</sub>17 differentiation (Fig. 7d), indicating that IL-6 presented *in trans* was efficient in preventing the TGF- $\beta$  mediated induction of CD96. We used hyper-IL-6 as a surrogate for IL-6 presented *in trans* and compared its effect to soluble IL-6 (and thus classic IL-6 signaling) during APC free differentiation of naive sorted (CD4<sup>+</sup>CD44<sup>+</sup>CD25<sup>-</sup>) T cells into T<sub>H</sub>17 cells. When using equimolar amounts of soluble IL-6 or hyper-IL-6, the induction of IL-17 in T cells was similar with both reagents (Fig. 7e). However, the suppression of IFN- $\gamma$  expression during T<sub>H</sub>17 differentiation was significantly more efficient with hyper-IL-6 than with soluble IL-6 (Fig. 7e). Because under certain conditions, Eomes is an inducer of IFN- $\gamma$  in CD4<sup>+</sup> T cells 24,25, we tested whether the increased fraction of IFN- $\gamma$ <sup>+</sup> T cells induced by TGF- $\beta$  plus soluble IL-6 was due to high Eomes expression. During T<sub>H</sub>17 differentiation, *Tbx21* and in particular *Eomes* mRNA were less efficiently suppressed by IL-6 than by hyper-IL-6, with no modulation of *Rorc* (Fig. 7f). Conversely, hyper-IL-6 was significantly more potent than soluble IL-6 in inducing robust GFP (IL-23R) expression during *in vitro* T<sub>H</sub>17 cell differentiation of naive CD4<sup>+</sup> T cells isolated from *Il23<sup>gfp/+</sup>* mice 26 (Fig. 7g, h), indicating that the higher IFN- $\gamma$  expression in T cells primed in *Il6<sup>ADC</sup>* mice was linked to lack of IL-6 trans-presentation in these mice.

Because high IFN- $\gamma$  expression in myelin-specific-T cells is associated with protection from EAE 27, we tested whether the high IFN- $\gamma$  expression observed in Foxp3<sup>-</sup> effector T cells in the *Il6<sup>ADC</sup>* mice might determine the resistance of *Il6<sup>ADC</sup>* mice to EAE. As measured by dye dilution, 2D2 T cells primed in *Il6<sup>ADC</sup>* mice proliferated as well as 2D2 T cells primed in *Il6<sup>flx/flx</sup>* control mice but showed higher production of IFN- $\gamma$  (Fig. 8a, b). Neutralization of IFN- $\gamma$  in *Il6<sup>ADC</sup>* mice with a monoclonal antibody to IFN- $\gamma$  fully restored EAE severity in *Il6<sup>ADC</sup>* mice compared to *Il6<sup>ADC</sup>* mice treated with a control antibody (Fig. 8c). In summary, these data imply that priming of T<sub>H</sub>17 cells in *Il6<sup>ADC</sup>* mice in the absence of DC-mediated IL-6 cluster signaling results in the exaggerated expression of IFN- $\gamma$  in CD4<sup>+</sup> T cells, most likely due to aberrant Stat3 activation in these cells.

## Discussion

Here, we show that T cells respond to IL-6 in the absence of IL-6R $\alpha$  expression through a process that we call IL-6 cluster signaling, in which DC-membrane bound IL-6R $\alpha$  complexed with IL-6 is presented *in trans* and sensed by gp130 molecules expressed on T cells. IL-6 cluster signaling not only substitutes for classic IL-6 signaling, but leads to qualitatively different T cell responses. The prototypic cytokine to be trans-presented by auxiliary cells via its high affinity receptor is IL-15 28. It is likely that similar to IL-15, IL-6 is loaded onto IL-6R $\alpha$  in endosomal compartments. Trans-presentation has also been proposed for another IL-6 family member, cardiotrophin-like cytokine, through binding to the CNTF receptor 29. Although IL-6 forms a stable complex with soluble IL-6R $\alpha$ , the affinity of IL-6 for IL-6R $\alpha$  is only about 0.5 to 1 nM 13, and thus two orders of magnitude lower than the affinity of IL-15 for IL-15R $\alpha$ . However, membrane bound cytokine trans-presentation was also reported for IL-2, whose affinity for IL-2R $\alpha$  is in the same range as the affinity of IL-6 for IL-6R $\alpha$  13,30.

When interacting with T cells, DC mediated IL-6 cluster signaling can restrict the IL-6 signal to cognate T cells, with high temporal synchronization with the TCR signal. Such coordination of signals leads to the imprinting of pathologic properties in recipient T cells. Notably, Foxp3 suppression is induced in T cells with reduced or even absent Stat3 signaling, and can be fully supported by classic IL-6 signaling. Therefore, the IL-6 that prevents the upregulation of Foxp3 in T cells does not have to be derived from the priming DC, and can be derived in soluble form from the micro-milieu. Hence, it is possible that the suppression of Foxp3 induction in T cells occurs as a "bystander" effect of ambient IL-6. However, the IL-6-dependent induction of inflammatory properties in Foxp3<sup>-</sup> T cells is only efficient in the context of antigen-presentation, and likely does not occur as a bystander effect of ambient IL-6. This suggests that IL-6-mediated pathogenic T cell differentiation passes through two checkpoints: the suppression of Foxp3 induction via classic IL-6 signaling and the initiation of a pathogenic effector T cell transcriptional program via IL-6 cluster signaling. Therefore, the ability to induce pathogenic T<sub>H</sub>17 cells is dependent on antigen presenting cells that can co-present IL-6 *in trans*.

Here, we show that IL-6<sup>+</sup>IL-6R $\alpha$ <sup>+</sup> DCs that are able to perform cluster signaling are CD103<sup>-</sup> and belong to the subset of CD11b<sup>+</sup>Sirp $\alpha$ <sup>+</sup> DCs that were recently classified as cDC2 31 and were previously associated with pathogenic T<sub>H</sub>17 responses 32. Because no mechanistic underpinning of the unique instructive capacity of this DC subset to instruct T<sub>H</sub>17 responses has been identified, IL-6 cluster signaling in the context of synchronized antigen presentation might be an intriguing hypothesis. In contrast to classic IL-6 signaling, IL-6 cluster signaling leads to an earlier and more robust expression of IL-23R in antigen-activated T cells. Therefore, facilitated sensing of IL-23 further supports their pathogenic phenotype 33. Vice versa, in the absence of IL-6 cluster signaling, IL-23 is unable to compensate for the impaired initiation of a pathogenic transcriptional program in antigen specific T cells, suggesting that the synchronization of antigen-specific priming and IL-6-mediated Stat3 signaling is fundamental for the pro-inflammatory phenotype of T cells. Because T cell blasts extensively downregulate cell surface expression of IL-6R $\alpha$ , it is plausible that IL-6 cluster signaling is a means to combine a "pathogenic" IL-6 signal with cognate re-activation. The APC type and the anatomical compartment of this process have not been exactly defined.

We provide evidence that lack of IL-6 cluster signaling during T<sub>H</sub>17 priming deviates the cytokine phenotype into IFN- $\gamma$  production, which is in part dependent on Eomes expression. Although there has been some controversy 34, IL-6 has been shown to suppress the development of Th1 cells via direct and indirect mechanisms 35. Here we demonstrate that IL-6 cluster signaling in particular is an efficient means to prevent the induction of IFN- $\gamma$  during T<sub>H</sub> cell differentiation. In our model, in the absence of IL-6 cluster signaling, insufficient Stat 3 activation, and thus a Stat1-Stat3 imbalance, allows for the expression of Eomes and IFN- $\gamma$  in T<sub>H</sub>17 priming conditions and results in impaired encephalitogenicity.

Finally, the possibility of IL-6 cluster signaling has implications for therapeutic interventions. Anti-IL-6 antibodies fail to inhibit IL-6 cluster signaling. The IL-6-IL-6R $\alpha$  complex formation occurs within DCs, most likely followed by targeted shuttling to plasma membrane regions involved in the cognate interaction with T cells, with immediate

accessibility to gp130 molecules on the T cell side. Therefore, site I of the IL-6 molecule 10, which mediates IL-6 binding to IL-6R $\alpha$  and is targeted by most anti-IL-6 antibodies, is already buried in the IL-6-IL-6R $\alpha$  complex when it appears at the plasma membrane. Although sgp130-Fc suppresses IL-6 trans-signaling 14, IL-6 cluster signaling is not inhibited by sgp130-Fc, and we hypothesize that sgp130-Fc cannot access the IL-6-IL-6R $\alpha$  complex at the DC-T cell interaction zone. However, similar to classic IL-6 signaling and IL-6 trans-signaling, IL-6 cluster signaling remains amenable to neutralization via anti-IL-6R $\alpha$  antibodies. Thus, IL-6 targeting strategies have to be carefully re-evaluated for the differential signaling modalities when designing therapeutic strategies for autoimmunity, chronic inflammation, and cancer.

## Online methods

### Generation of *Il6*<sup>RD</sup> mice

To generate a new conditional IL-6 reporter/deleter strain [*Il6*<sup>RD</sup>; *Il6*<sup>m3307(Cerulean-P2A-CD90.1)Arte</sup>] allowing for detection and specific depletion of IL-6 producing cells, we targeted Exon 2 of the *Il6* locus on chromosome 5 by insertion of a loxP-flanked transcription termination cassette (STOP) followed by a reporter cassette. The reporter expression cassette comprised (i) fluorescent reporter Cerulean, PCR-amplified from the cloning vector pDH51-GW-CFP; (ii) 2A peptide from *Porcine teschovirus-1* (P2A), the aa sequence GSGATNFSLLKQAGDVEENPGP 36 was synthetically attached to the adjacent sequences using oligonucleotides; (iii) Thy1.1 (CD90.1) surface protein, that is in C57BL/6 mice (endogenously expressing allele Thy1.2 [CD90.2]) exclusively expressed on *Il6* reporter positive cells. The sequence was provided by M. Schmidt-Supprian and is identical to the GenBank # AAR17087.1; (iv) a polyadenylation signal BGH pA, derived from the plasmid pcDNA3.1(+). A targeting vector MW21214 containing the floxed STOP cassette and the reporter expression cassette was generated. To target this construct to the *Il6* locus, homologous arms were amplified from BAC clone C57BL/6J RPCIB-731. The SHA (short homologous arm) encompassed ~4kb upstream of *Il6*, Exon1, Intron 1 and 31 nucleotides of Exon 2. The natural Exon 1 contains the 5'UTR and the translation initiation codon (START) which was mutated in the targeting vector (noSTART) by site directed mutagenesis (from ATG into AAG) in order to prevent transcription of the remaining mouse *Il6* gene. Downstream of the expression cassette, a positive selection marker (CAGGS promoter driven puromycin resistance) was inserted, that was flanked by FRT sites allowing for Flp-mediated deletion of the selection marker. The downstream LHA (long homologous arm) consisting of 5.7 kb of the *Il6* gene encompassed the remaining 153 nucleotides of exon 2, the complete intron 2, exon 3, intron 3, exon 4, and a partial intron 4. With the exception of the mutated start codon in exon 1, the genomic sequence was left intact, in order to preserve all potential regulatory elements of *Il6*. For negative selection, a PGK promoter driven HSV TK was inserted. The targeting vector MW21214 was approved by complete sequencing, linearized by NotI and transfected into the C57BL/6N ES cell line Art B6 3.6 by electroporation to generate heterozygous targeted ES cells. Homologous recombinant clones were isolated using positive (PuroR) and negative (TK) selections. Clones were screened by PCR, resulting in 22% targeting frequency. The majority of the clones analyzed carried the inserted point mutation of the start codon. Four clones were

expanded and validated by Southern Blot and PCR analyses. Targeted ES cells were injected into blastocysts (isolated at dpc 3.5 from superovulated, mated BALB/c females). Injected blastocysts were transferred into pseudopregnant NMRI females (2.5 days post coitum). Chimerism was evaluated by coat color and highly chimeric mice were bred to Flp-Deleter mice (C57BL/6-Tg<sup>(CAG-Flpe)</sup>2Arte), allowing for (i) identification of germline transmission and (ii) Flp-mediated deletion of the positive selection marker. *Il6<sup>RD</sup>* mice were crossed with CMV-Cre [Tg(CMV-cre)<sup>1Cgn</sup>] for ubiquitous expression or with CD11c-Cre [Tg(*Itgax-cre*)<sup>1-1Reiz</sup>] mice for DC-specific, conditional expression of the reporter cassette after Cre-mediated removal of the STOP cassette. Under control of the endogenous *Il6* promoter, a chimeric transcript harboring the Cerulean ORF fused to the P2A sequence and the CD90.1 ORF is expressed. The P2A provides effective co-translational cleavage *in vitro* and *in vivo*, resulting in strict stoichiometric co-expression of individual Cerulean and CD90.1 proteins with correct subcellular localization (cytoplasm or cell surface, respectively).

## Mice

*Il6<sup>flox/flox</sup>* [*Il6*<sup>tm1.1Jho</sup>] 8,37, *Foxp3.gpfKI* [*Foxp3<sup>tm1Kuch</sup>*] 5,36,38, *Il23r.gfp KI* [*Il23r<sup>tm1Kuch</sup>*] 26 and MOG<sub>35-55</sub> specific TCR transgenic 2D2 mice [Tg(*Tcra2D2, Tcrb2D2*)<sup>1Kuch</sup>] 39 were described previously. *Il6<sup>-/-</sup>* [*Il6<sup>tm1Kopf</sup>*] were obtained from Jackson Laboratory. *Il6ra<sup>flox/flox</sup>* mice were kindly provided by Thomas Wunderlich 40. OVA<sub>323-339</sub> specific TCR transgenic OT II mice [Tg(*TcraTcrb*)<sup>425Cbn</sup>] with the congenic marker CD45.1 were kindly provided by D. Busch (Institute for Medical Microbiology, Immunology and Hygiene, TU Munich). *Stat3<sup>flox/flox</sup>* mice [Stat3<sup>tm2Aki</sup>] were received from F. Greten (Institute for Tumor Biology and Experimental Therapy, Georg-Speyer Haus, Frankfurt). sgp130-Fc transgenic mice were previously described 41. For the EAE experiments reported in supplementary Fig. 10, opt\_sgp130-Fc mice were used. To generate mice with cell-type specific excision of floxed cassettes, floxed mice were bred with CD11c Cre [Tg(*Itgax-cre*)<sup>1-1Reiz</sup>], CD4 Cre [Tg(*Cd4-cre*)<sup>1Cwj</sup>], CD19 Cre [*Cd19<sup>tm1(cre)Cgm</sup>*] or LysM Cre [*Lyz2<sup>tm1(cre)Ifö</sup>*], respectively (all from Jackson Laboratory). To visualize Cre-expressing cells, for some experiments a Cre reporter allele Gt(ROSA)26Sor<sup>tm1(EYFP)Cos</sup> was crossed in. All mouse strains were on pure C57BL/6 background. Animals were kept in a specific pathogen-free facility at the TU Munich or Johannes Gutenberg University Mainz. All experimental protocols were approved by the standing committee for experimentation with laboratory animals of the Bavarian or Rhine Palatinate state authorities and carried out in accordance with the corresponding guidelines (AZ 55.2-1-54-2532-29-13, AZ 55.2-1-54-2532-95-14 and 23 177-07/G 13-1-099).

## Induction of EAE

To induce EAE, mice were immunized *s.c.* (base of tail) with 200 µl of an emulsion containing 200 µg MOG<sub>35-55</sub> (MEVGWYRSPFSRVVHLYRNGK; Auspep, Tullamarine, Australia) and 500 µg *M. tuberculosis* H37Ra (BD Difco) in CFA and received 200 ng PTx (Sigma) *i.v.* on the same day and 2 d after the immunization. Clinical signs of disease were monitored as described previously 42. To ablate *Il6* reporter (Thy1.1) expressing cells, mice were treated with *i.p.* injections of anti-Thy1.1 antibodies (19E12) or isotype control antibodies (mouse IgG2a; C1.18.4). For *in vivo* neutralization of IFN-γ, mice received anti-IFN-γ antibodies (R4-6A2) or isotype control antibodies (rat IgG1; HRPN). Antibodies

were obtained from BioXCell and were injected at a dose of 200 µg starting one day after immunization followed by injections every other day until the development of first signs of disease. For adoptive transfer experiments, mice of the indicated genotypes received  $2.5 \times 10^6$  naïve GFP (Foxp3)<sup>-</sup> 2D2 cells *i.v.* one day prior to immunization.

### Preparation of CNS mononuclear cells

At the peak of disease, CNS-infiltrating cells were isolated after perfusion through the left cardiac ventricle with PBS. Brain and spinal cord were dissected and digested with collagenase D (2.5 mg/ml) and DNase I (1 mg/ml) at 37°C for 45 min. After passing the tissue through a 70 µm cell strainer, cells were separated by discontinuous Percoll gradient (70%/37%) centrifugation. Mononuclear cells were isolated from the interphase.

### Preparation of naïve T cells and differentiation of T helper cell subsets

Naïve T helper cells were isolated from peripheral lymph nodes and spleens. Naïve T cells were isolated using magnetic beads (Naïve CD4<sup>+</sup> T Cell Isolation Kit, Miltenyi Biotec) or subsequent to enrichment of T helper cells (CD4<sup>+</sup> T Cell Isolation Kit, untouched, Miltenyi Biotec) by FACS (CD4<sup>+</sup>CD44<sup>low</sup>GFP (Foxp3)<sup>-</sup>). For T helper cell differentiation, naïve T cells were stimulated for 3 days with plate-bound antibody to CD3 (145-2C11, 4 µg/ml) and soluble antibody to CD28 (PV-1, 2 µg/ml). Recombinant cytokines were added to the differentiation cultures as indicated: human TGF-β1 (0.25 to 2 ng/ml) and/or mouse IL-6 (50 ng/ml), all R&D Systems. Cells were cultured in Dulbecco's Modified Eagle medium (DMEM) supplemented with 10% FCS, 50 µM β-mercaptoethanol, nonessential amino acids (MEM-NEAA), MEM Vitamins, Folic Acid, 50 U/ml penicillin, 50 µg/ml streptomycin and 0.1 mg/ml Gentamicin. In some experiments, we compared the capacity of soluble IL-6 vs hyper-IL-6 19. Here, we differentiated naïve T cells of the indicated genotypes in the presence of TGF-β (0.1 to 0.5 ng/ml) and equimolar amounts of hyper-IL-6 and human IL-6.

### Isolation of DCs

Peripheral lymph nodes and spleens were injected with digestion mix (1mg/ml Collagenase D and 20 µg/ml DNase I [Roche], 2% FCS in HEPES-buffered RPMI-1640). Organs were fragmented and incubated at 37°C for 45 min. To disrupt cell complexes, 10 mM EDTA was added for additional 5 min. Cell suspensions were passed through 100 µm cell strainers.

### Generation and culture of BMDCs

Bone marrow derived DCs were generated by flushing out femora and tibiae. Viable cells were cultured in clone medium supplemented with GM-CSF and IL-4 (both 20 ng/ml, R&D Systems) for 6 days with splitting every other day. DCs were removed by vigorous pipetting and cultured in the presence of TLR ligands CpG [ODN 1826] from InVivoGen or LPS [*E.coli* 0111:B4 Lipopolysaccharide], Sigma-Aldrich.

### BMDC / T cell co-culture

Naïve 2D2 T cells were pre-cultured overnight (at a ratio of 1:4) with splenocytes or BMDCs from *Il6<sup>flox/flox</sup>* mice, *Il6<sup>-/-</sup>* mice, or *Il6<sup>ADC</sup>* mice in the presence of 50 µg/ml

MOG<sub>35-55</sub>. For some experiments naïve 2D2 and OT II T cells were pre-cultured with BMDCs of the indicated genotypes in the presence of either MOG<sub>35-55</sub> or OVA<sub>323-339</sub> (ISQAVHAAHAEINEAGR; Auspep, Tullamarine, Australia). LPS (0.5 µg/ml) was added and cells were harvested at the indicated time points for analysis. In some experiments, Marimastat (3 µM, Sigma-Aldrich) was added to block IL-6R $\alpha$  shedding. To analyze different IL-6 signaling modes, blocking agents were added in equimolar concentrations: anti-IL6 (Polyclonal Goat IgG, R&D or monoclonal mAb#8, Ref. 43), anti-IL6R (MR16-1), and sgp130-Fc 14.

### Flow cytometry and intracellular cytokine staining

Cells were stained with live/dead fixable dyes (Aqua [405 nm exc] or Near-IR [633 nm exc], Invitrogen) and antibodies to surface markers: CD3 (clone 145-2C11), CD4 (GK1.5 or RM4-5), CD11b (M1/70), CD11c (HL3), CD19 (6D5), CD25 (PC61), CD44 (IM7), CD45.1 (A20), CD45.2 (104), CD69 (H1.2F3), Thy1.1 (CD90.1, Ox-7), CD96 (3.3), CD103 (2E7), CD126 (IL-6R $\alpha$ , D7715A7), CD130 (gp130, KGP130), CD172 (SIRP $\alpha$ , P84), 2D2 TCR V $\alpha$ 3.2 (RR3-16) V $\beta$ 11 (RR3-15), Ly6G (1A8), MHC II (M5/114.15.2), NK1.1 (PK136), SiglecH (eBio440c); all BD Biosciences, eBioscience or BioLegend. For intracellular cytokine staining, cells were re-stimulated with 50 ng/ml PMA (Sigma-Aldrich), 1 µg/ml ionomycin (Sigma-Aldrich) and monensin (1 µl/ml BD GolgiStop) at 37 °C for 2.5 h. Subsequent to live/dead and surface staining, cells were fixed and permeabilized (Cytofix/Cytoperm and Perm/Wash Buffer; BD Biosciences), and stained for cytokines IL-17A (TC11-18H10.1; BioLegend), IFN- $\gamma$  (XMG1.2, eBioscience), IL-10 (JES5-16E3, BD Biosciences), and GM-CSF (MP1-22E9, BD Biosciences). For intracellular staining of IL-6 in BMDCs, cells were stimulated with TLR ligands for 3 h before adding 5 µg/ml Brefeldin A (Sigma-Aldrich) for further 2 h. Subsequent to live/dead and surface staining, fixation and permeabilization, cells were stained for IL-6 (MP5-20F3, BD). For intranuclear staining of Foxp3 (FJK-16s, eBioscience), cells were stained for live/dead discrimination and surface markers. Fixation, permeabilization, and intranuclear staining were performed according to the manufacturer's instructions (Transcription Factor Staining Buffer Set, eBioscience). To analyze Stat3 activation, cells were fixed with Phosflow Lyse/Fix Buffer (BD) for 10 min at 37 °C, permeabilized with PhosFlow Perm Buffer III (BD) for 30 min on ice and stained simultaneously for surface markers and Tyrosine 705 phosphorylated Stat3 (4/P-STAT3, BD) according to the manufacturer's instructions. Cells were analyzed using a CyAn ADP 9 flow cytometer (Beckman/Coulter) and FlowJo software (Tree Star).

### Detection of antigen specific T cells *ex vivo*

MOG specific cytokine producing T helper cells were analyzed around day 7 to 8 after immunization. Single cell suspensions from draining lymph nodes or spleens were restimulated with 30 µg/ml MOG<sub>35-55</sub> for 6 h in the presence of 5 µg/ml Brefeldin A during the last 3 h of incubation followed by surface and intracellular cytokine staining as described above. MOG specific T cells were detected via staining of fixed and permeabilized cells with biotinylated anti-CD40L (CD154, clone MR1, eBioscience) and fluorochrome-coupled Streptavidin.

## ELISA

IL-6 amounts in cell culture supernatant and in the serum of immunized mice were quantified using standard sandwich ELISA (R&D Systems, DuoSet). Standard curves and sample concentrations were calculated based on the mean of triplicates for each dilution or sample.

## Quantitative PCR analysis

For quantitative PCR, RNA was extracted using RNeasy columns (Qiagen). cDNA was transcribed using TaqMan Reverse Transcription Reagents as recommended (Applied Biosystems) and used as template for quantitative PCR. Primer plus FAM-labelled probe mixtures were obtained from Applied Biosystems (*Il1b*: Mm00434228\_m1; *Il6*: Mm99999064\_m1; *Il12a* (p35): Mm00434165\_m1; *Il12b* (p40): Mm01288989\_m1; *Il23a* (p19): Mm00518984\_m1; *Eomes*: Mm01351985\_m1; *Rorc*: Mm00441144\_g1; *Tbx21*: Mm00450960\_m1). The gene expression was normalized to the expression of  $\beta$ -actin (ACTB, VIC-labelled probe).

## RNA Seq

Total RNA was isolated from FACS sorted 2D2 GFP (Foxp3)<sup>-</sup> T cells re-isolated from draining lymph nodes after priming in *Il6<sup>fllox/fllox</sup>* host mice, *Il6<sup>-/-</sup>* host mice, or *Il6<sup>ADC</sup>* host mice. Three biological replicates were prepared for each condition. Total RNA was further purified with AmpureXP beads to remove impurities detected by UVvis spectrometry. This RNA was used to construct sequencing libraries using the Encore Complete RNA-Seq library system (NuGen Inc. Santa Clara, USA) according to the instructions of the manufacturer. In brief 125 ng of total RNA were treated with heat-labile ds DNase (Thermo Scientific Inc., MA, USA) to remove residual DNA and used for mixed random-/polyA-primed first-strand cDNA synthesis. After second strand synthesis the double-stranded cDNA was fragmented by sonication (Covaris M220; power 50 W, duty factor 20, 200 cycles p. burst, 115 s treatment time). The fragmented cDNA was end repaired and ligated with sample-specific barcoded adaptors. After strand selection, the library was amplified (4 cycles, 94 °C 30 sec, 55 °C 30 sec, 72 °C 60 sec and 12 cycles 94 °C 30 sec, 63 °C 30 sec, 72 °C 60 sec) and purified and size-selected with AMPure XP beads (Beckman Coulter, CA, USA). Resulting libraries were quantified on a Bioanalyzer 2100 (Agilent, Santa Clara, USA). The barcoded libraries were pooled at 10 nM concentration for multiplexed sequencing. All libraries were sequenced on a HiSeq 1500 as 100 b single reads to a depth of 25-30 Mio raw reads per sample. After demultiplexing of sequence data, adaptor sequences and polyA tails were removed and each library was mapped to the murine reference genome mm10 with the spliced-read aligner STAR 4.4. Based on the mapping results, sequence reads for annotated genes were counted with HTSeq 0.6.1. Comparative analyses of gene expression were performed with the DESeq2 package 1.10.1 as pairwise comparison of two groups for each combination of interest. The false discovery rate for detection of differentially abundant transcripts was set to 5 %.

For gene set enrichment analysis (GSEA) a ranked list of the fold change of RNA Seq read values or nanostring signals between wild primed and *Il6<sup>ADC</sup>* primed effector T cells isolated from draining lymph nodes was calculated. The java GSEA Desktop Application v2.2.1, was

used in conjunction with the Molecular Signatures Database v45.1 to run the analysis. Data analysis of differentially enriched genes in wild type-primed and *Il6<sup>ADC</sup>* primed Foxp3<sup>+</sup> 2D2 T cells was performed through the use of QIAGEN's Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)). The Molecule Activity Predictor (MAP) tool was used to investigate the effect of IL-6 signaling pathways on identified IL-6 target genes.

### **Immunofluorescence, proximity ligation assay (PLA), and confocal microscopy**

Naïve 2D2 T cells were cultured at a ratio of approximately 4:1 with CellTracker Deep Red (Molecular Probes) labeled BMDCs in chamber slides in the presence of MOG<sub>35-55</sub> to form immunological synapses. Subsequent to LPS stimulation for 80 min, cells were fixed with ice-cold methanol, blocked and permeabilized in PBS containing 10% normal goat serum, 1% BSA and 0.2% Triton X-100. Incubation with primary antibody specific for IL-6 (polyclonal goat IgG, R&D) diluted in PBS supplemented with 1% BSA and 0.1% Tween 20 was carried out overnight at room temperature. Secondary Antibody (chicken anti-goat IgG\_AF 488 conjugate; Invitrogen) was diluted in PBS supplemented with 1% BSA and 0.1% Tween 20 and incubated for one hour at room temperature. Samples were mounted with ProLong Gold Antifade Reagent with DAPI (Molecular Probes) for nuclear counterstaining.

To visualize IL-6-IL-6R $\alpha$  complexes, a proximity ligation assay (PLA) was performed according to the manufacturer's instructions (Duolink In Situ Red Kit Goat/Rabbit, Sigma-Aldrich) using primary antibodies specific for IL-6 (polyclonal goat IgG, R&D) and IL-6R $\alpha$  (polyclonal rabbit IgG M-20, Santa Cruz).

Confocal image stacks were recorded on a confocal microscope (Olympus FV1000) equipped with x60/1.42 N.A. oil-immersion objective. All images were acquired sequentially. Maximum intensity projections and xz representations were generated using the open-source image analysis software Fiji 47. Gamma was adjusted nonlinearly to enhance visibility of morphological details.

### **Statistical analysis**

Statistical evaluations of cell frequency measurements, cell numbers, mRNA amounts, and protein levels were performed with the unpaired Student's t test when two populations were compared. Two-tailed p values < 0.05 were considered significant. Multiple comparisons were performed with one-way ANOVA followed by post-hoc multiple comparisons tests as indicated in the legends to the figures. EAE scores between groups were analyzed as disease burden per individual day with one-way-ANOVA and post-hoc test as indicated.

### **Data availability statement**

For materials, protocols, and supporting data please place requests to the corresponding author TK ([thomas.korn@tum.de](mailto:thomas.korn@tum.de)).



## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


The authors thank all members of the Korn laboratory for their various inputs. We also thank B. Kunze, B. Lunk and colleagues for expert mouse care. We are grateful to B. Stockinger (MRC National Institute for Medical Research, London) for kindly providing the 19E12 hybridoma and to M. Kopf (ETH, Zürich) for providing *IL21r<sup>-/-</sup>* mice. This work was supported by the Deutsche Forschungsgemeinschaft (TRR128 to AW and TK, TRR156 to AW, WA1600/8-1 to AW, SFB1054-B07 to TK, SyNergy to TK, SFB877-A01 to SJR, SFB877-A10 to Christoph Garbers (CG), and the cluster of excellence “Inflammation at interfaces” to SRJ and CG) and by the ERC (CoG 647215 to TK). JH is supported by SAF2011-23272 and SAF2014-56546-R.

## References

- Hall AO, et al. The Cytokines Interleukin 27 and Interferon- $\gamma$  Promote Distinct Treg Cell Populations Required to Limit Infection-Induced Pathology. *Immunity*. 2012; 37:511–523. [PubMed: 22981537]
- Neufert C, et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. *Eur J Immunol*. 2007; 37:1809–1816. [PubMed: 17549733]
- Huber M, et al. IL-27 inhibits the development of regulatory T cells via STAT3. *Int Immunol*. 2008; 20:223–234. [PubMed: 18156621]
- Dardalhon V, et al. IL-4 inhibits TGF- $\beta$ -induced Foxp3+ T cells and, together with TGF- $\beta$ , generates IL-9+ IL-10+ Foxp3(-) effector T cells. *Nat Immunol*. 2008; 9:1347–1355. [PubMed: 18997793]
- Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature*. 2006; 441:235–238. [PubMed: 16648838]
- Serada S, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci USA*. 2008; 105:9041–9046. [PubMed: 18577591]
- Ghoreschi K, et al. Generation of pathogenic T(H)17 cells in the absence of TGF- $\beta$  signalling. *Nature*. 2010; 467:967–971. [PubMed: 20962846]
- Lee Y, et al. Induction and molecular signature of pathogenic TH17 cells. *Nat Immunol*. 2012; 13:991–999. [PubMed: 22961052]
- Gaublomme JT, et al. Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity. *Cell*. 2015; 163:1400–1412. [PubMed: 26607794]
- Boulanger MJ, Chow D-C, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. *Science (New York NY)*. 2003; 300:2101–2104.
- Babon JJ, Varghese LN, Nicola NA. Inhibition of IL-6 family cytokines by SOCS3. *Semin Immunol*. 2014; 26:13–19. [PubMed: 24418198]
- Tamura T, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. *Proc Natl Acad Sci USA*. 1993; 90:11924–11928. [PubMed: 8265649]
- Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. *Biochem J*. 1994; 300(Pt 2):281–290. [PubMed: 8002928]
- Jostock T, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. *Eur J Biochem*. 2001; 268:160–167. [PubMed: 11121117]
- Korn T, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. *Nature*. 2007; 448:484–487. [PubMed: 17581588]
- Durant L, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. *Immunity*. 2010; 32:605–615. [PubMed: 20493732]
- Baran P, Nitz R, Grötzinger J, Scheller J, Garbers C. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. *Journal of Biological Chemistry*. 2013; 288:14756–14768. [PubMed: 23564454]

18. Palacios R, Steinmetz M. IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. *Cell*. 1985; 41:727–734. [PubMed: 3924409]
19. Fischer M, et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. *Nat Biotechnol*. 1997; 15:142–145. [PubMed: 9035138]
20. White J, et al. The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. *Cell*. 1989; 56:27–35. [PubMed: 2521300]
21. Söderberg O, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. *Nat Methods*. 2006; 3:995–1000. [PubMed: 17072308]
22. Linker RA, et al. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood-brain barrier. *J Neuroimmunol*. 2008; 205:64–72. [PubMed: 18950871]
23. Nurieva R, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. *Nature*. 2007; 448:480–483. [PubMed: 17581589]
24. Suto A, Wurster AL, Reiner SL, Grusby MJ. IL-21 inhibits IFN-gamma production in developing Th1 cells through the repression of Eomesodermin expression. *J Immunol*. 2006; 177:3721–3727. [PubMed: 16951332]
25. Yagi R, et al. The transcription factor GATA3 actively represses RUNX3 protein-regulated production of interferon-gamma. *Immunity*. 2010; 32:507–517. [PubMed: 20399120]
26. Awasthi A, et al. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. *J Immunol*. 2009; 182:5904–5908. [PubMed: 19414740]
27. Chu CQ, Wittmer S, Dalton DK. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. *J Exp Med*. 2000; 192:123–128. [PubMed: 10880533]
28. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. *Immunity*. 2002; 17:537–547. [PubMed: 12433361]
29. Plun-Favreau H, et al. The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine. *EMBO J*. 2001; 20:1692–1703. [PubMed: 11285233]
30. Wuest SC, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. *Nat Med*. 2011; 17:604–609. [PubMed: 21532597]
31. Tussiwand R, Gautier EL. Transcriptional Regulation of Mononuclear Phagocyte Development. *Front Immun*. 2015; 6:533.
32. Lewis KL, et al. Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine. *Immunity*. 2011; 35:780–791. [PubMed: 22018469]
33. Croxford AL, Mair F, Becher B. IL-23: One cytokine in control of autoimmunity. *Eur J Immunol*. 2012; 42:2263–2273. [PubMed: 22949325]
34. Tanaka T, et al. Enhancement of T helper2 response in the absence of interleukin (IL)-6; an inhibition of IL-4-mediated T helper2 cell differentiation by IL-6. *Cytokine*. 2001; 13:193–201. [PubMed: 11237426]
35. Diehl S, Rincón M. The two faces of IL-6 on Th1/Th2 differentiation. *Mol Immunol*. 2002; 39:531–536. [PubMed: 12431386]
36. Kim JH, et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. *PLoS ONE*. 2011; 6:e18556. [PubMed: 21602908]
37. Quintana A, et al. Astrocyte-specific deficiency of interleukin-6 and its receptor reveal specific roles in survival, body weight and behavior. *Brain Behav Immun*. 2013; 27:162–173. [PubMed: 23085146]
38. Korn T, et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. *Nat Med*. 2007; 13:423–431. [PubMed: 17384649]
39. Bettelli E, et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. *J Exp Med*. 2003; 197:1073–1081. [PubMed: 12732654]


40. Wunderlich FT, et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. *Cell Metab.* 2010; 12:237–249. [PubMed: 20816090]
41. Rabe B, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. *Blood.* 2008; 111:1021–1028. [PubMed: 17989316]
42. Korn T, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. *Proc Natl Acad Sci USA.* 2008; 105:18460–18465. [PubMed: 19015529]
43. Brakenhoff JP, Hart M, De Groot ER, Di Padova F, Aarden LA. Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. *J Immunol.* 1990; 145:561–568. [PubMed: 1694882]
44. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013; 29:15–21. [PubMed: 23104886]
45. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics.* 2015; 31:166–169. [PubMed: 25260700]
46. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 2014; 15:550. [PubMed: 25516281]
47. Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods.* 2012; 9:676–682. [PubMed: 22743772]



**Figure 1. IL-6-producing cells during MOG<sub>35-55</sub> induced EAE.**

Using a novel reporter mouse, IL-6 producing cells were identified by Thy1.1 and cerulean. (a) Control animals or CMV Cre x *I16<sup>RD/wt</sup>* mice were immunized and splenocytes were analyzed on day 7 for IL-6 (Thy1.1) expression in the indicated cell populations (of CD45<sup>+</sup> cells) after 4 h *ex vivo* PMA/ionomycin stimulation. Representative cytograms out of two experiments. (b) Kinetics of IL-6 (Thy1.1) expression in draining lymph node (dLN) DCs of DC conditional IL-6 reporter mice (CD11c Cre x *I16<sup>RD/wt</sup>* x R26 *Stop<sup>flox/flox</sup>* YFP) on different days after immunization. DCs were defined as YFP<sup>+</sup>CD11c<sup>+</sup>MHC class II<sup>high</sup> and


analyzed for IL-6 (Thy1.1) and Sirpα (CD172a) after 4 h *ex vivo* stimulation with PMA/ionomycin. Mean ± SD, n=4 (c) IL-6 (Thy1.1)-expressing cells in the CNS at the peak of EAE (day 16) after *ex vivo* PMA/ionomycin stimulation. Representative cytograms out of two experiments. (d) DC conditional IL-6 reporter mice were immunized followed by treatment with isotype (mouse IgG2a) or anti-Thy1.1 (19E12) to deplete IL-6 (Thy1.1)<sup>+</sup> DCs. On day 7, CD4<sup>+</sup> T cells from dLN were assessed for cytokine production after *ex vivo* re-stimulation with PMA/ionomycin. Representative cytograms out of five mice analyzed per group. (e) EAE in control treated or anti-Thy1.1 treated DC conditional IL-6 reporter mice. Representative of two experiments. Mean EAE scores + SEM, n=6. (f) EAE in mice with DC conditional deletion of *Il6* (CD11c Cre x *Il6<sup>lox/lox</sup>*, *Il6<sup>ADC</sup>*). Representative of four experiments. Mean EAE scores + SEM, n=7. \*P<0.05, ANOVA plus Fisher's LSD test for individual days.



**Figure 2. Conditional ablation of *Il6* in DCs results in delayed Stat3 activation in antigen specific T cells but does not impair the suppression of Foxp3 induction.**

(a) Naive MOG<sub>35-55</sub> specific T cells (2D2) were transferred into control hosts (*Il6<sup>flox/flox</sup>*), *Il6<sup>-/-</sup>* mice, or DC conditional IL-6 deficient mice (*Il6<sup>ADC</sup>*) followed by immunization with MOG<sub>35-55</sub>. After 3 weeks, donor cells were re-isolated from dLN and analyzed for Foxp3 expression. Representative of two experiments. Mean + SD, n=4, \*P<0.005, ANOVA plus Tukey's test. (b) RNA seq was performed in re-isolated Foxp3<sup>+</sup> 2D2 T cells, and IL-6 hallmark genes were analyzed in cells derived from control vs *Il6<sup>ADC</sup>* host mice. (c)


Splenocytes from *Il6<sup>flox/flox</sup>* control mice, *Il6<sup>-/-</sup>* mice, or *Il6<sup>ADC</sup>* mice were co-cultured with naive 2D2 T cells in the presence of antigen and Marimastat. In control cultures exogenous recombinant IL-6 was added instead of LPS (left histogram). At several time points after addition of LPS, Stat3 phosphorylation was analyzed in 2D2 T cells. p-Stat3 was delayed in cultures with *Il6<sup>ADC</sup>* splenocytes compared to control splenocytes (2h) although the amount of soluble IL-6 was similar at this time point (**d**). Representative of two experiments. Mean + SD, n=3. (**e, f**) Naive control (*Stat3<sup>flox/flox</sup>*) or Stat3 deficient (CD4 Cre x *Stat3<sup>flox/flox</sup>*, *Stat3<sup>ΔT</sup>*) T cells were activated with anti-CD3/anti-CD28 in the presence of TGF-β plus IL-6. Intracellular cytokine staining after PMA/ionomycin stimulation (**e, left**) and nuclear staining for Foxp3 (**e, right**) on day 3 of culture. (**f**) Relative suppression of Foxp3 and frequencies of cytokine positive cells in control or *Stat3<sup>ΔT</sup>* T cells in response to IL-6 (50 ng/ml) and graded amounts of TGF-β. Representative of three experiments.



**Figure 3. IL-6 presentation *in trans* is a functional IL-6 signaling modality in engineered murine pre-B-cells (Ba/F3) and is not blocked by sgp130-Fc.**

Ba/F3 cells stably transduced with the human IL-6R $\alpha$  (termed Ba/F3-IL-6R $\alpha$ ) show no GFP fluorescence whereas Ba/F3-gp130-eGFP cells stably transduced with gp130-eGFP (termed Ba/F3-gp130-eGFP) appear bright green. **(a)** Equal amounts of either Ba/F3-IL-6R $\alpha$  (**left**) or Ba/F3-gp130-eGFP cells (**right**) were cultured for two days with either 10 ng/ml human IL-6, 10 ng/ml hyper-IL-6, 10 ng/ml hyper-IL-6 plus 1  $\mu$ g/ml sgp130-Fc, 1% conditioned WEHI-supernatant (containing IL-3), or left untreated (Medium). Mean RLU  $\pm$  SD (n=3, representative of three experiments). **(b)** Ba/F3-IL-6R and Ba/F3-gp130-eGFP cells were co-cultured in a 1:10 ratio for two days. Cells were stimulated with 10 ng/ml IL-6, 10 ng/ml IL-6 plus 1  $\mu$ g/ml sgp130-Fc, 10 ng/ml IL-6 plus 1  $\mu$ g/ml of the anti-IL-6 antibody mAb#8, 10 ng/ml IL-6 plus anti-IL-6R antibody tocilizumab, or were left untreated. Mean RLU  $\pm$  SD (n=3, representative of three experiments). **(c)** Ba/F3-IL-6R and Ba/F3-gp130-eGFP cells were co-cultured in a 1:10 ratio for two days either without or with 10 ng/ml IL-6. Microscopic pictures were taken on days as indicated. Pictures are representative of three independent experiments. \*P<0.05, ANOVA plus Tukey's multiple comparisons test.






**Figure 4. DCs perform IL-6 cluster signaling during antigen specific priming of T cells.**


(a) 2D2 T cells were cultured in the presence of MOG<sub>35-55</sub> with WT, *Il6*<sup>-/-</sup>, or *Il6ra*<sup>-/-</sup> BMDCs. Subsequent to LPS stimulation, Stat3 phosphorylation was assessed in 2D2 T cells and plotted as  $\Delta$ MFI. Representative of four experiments. Mean + SD, n=2, P<0.05, ANOVA plus Tukey's multiple comparisons test. (b) IL-6 was measured by ELISA in the supernatants of (a). (c) WT BMDCs were co-cultured with either control CD4<sup>+</sup> T cells or IL-6R $\alpha$  deficient T cells in the presence of SEB followed by LPS stimulation. Stat3 activation was measured in TCR-V $\beta$ 8<sup>-</sup> vs TCR-V $\beta$ 8<sup>+</sup> T cells (SEB responders). As control, p-Stat3 triggered by exogenous IL-6 was assessed (blue). Representative of two experiments. Mean + SD, n=2, P<0.05, ANOVA plus Tukey's multiple comparisons test. (d,

**e)** Triple cultures of WT BMDCs with 2D2 T cells and OT II T cells were stimulated with either MOG<sub>35-55</sub> or OVA<sub>323-339</sub>. At different time points after addition of LPS p-Stat3 was measured in 2D2 or OT II T cells. Representative histograms at 2 h (**d**) and time course (**e**). Representative of two experiments. (**f**) WT BMDCs were cultured with 2D2 T cells and MOG<sub>35-55</sub> in the presence of exogenous IL-6 or with LPS and 1µg/ml blocking agents (anti-IL-6R, anti-IL-6, or sgp130-Fc). After 2h, p-Stat3 was analyzed. Representative of four experiments. Mean + SD, n=4. \*P<0.04, ANOVA plus Tukey post test. (**g**, **h**). 2D2 T cells were cultured with mixtures of BMDCs followed by assessment of p-Stat3 in 2D2 T cells (**g**) and BMDCs (**h**). Representative of three experiments, mean + SD, n=2. \*P<0.05, ANOVA plus Tukey's multiple comparisons test.



**Figure 5. The IL-6-IL-6R $\alpha$  complex is formed in intracellular compartments of DCs and presented *in trans* to cognately interacting T cells.** 2D2 T cells were cultured in the presence of MOG<sub>35-55</sub> with WT, *Il6*<sup>-/-</sup>, or *Il6ra*<sup>-/-</sup> BMDCs that were pre-stained with CellTracker. Subsequent to LPS stimulation for 80 min, cells were fixed and permeabilized. **(a)** Immunofluorescence staining of IL-6 (green) in co-cultures of T cells (arrows) with *Il6*<sup>-/-</sup> BMDCs (upper row) or WT BMDCs (lower row). Nuclei of both cell types were stained with DAPI (white). The arrow head highlights an IL-6 signal at the DC-T cell interface. Scale bar = 10  $\mu$ m. Representative of four experiments. **(b)**


Proximity ligation assay analyses for IL-6-IL-6R $\alpha$  interactions (green) in BMDCs interacting with 2D2 T cells. Co-cultures of 2D2 T cells with *Il6*<sup>-/-</sup> BMDCs, *Il6ra*<sup>-/-</sup> BMDCs, or WT BMDCs were stimulated with LPS. After 80 min cells were fixed and subjected to PLA. Nuclei (DAPI), BMDCs (CellTracker), and IL-6-IL-6R $\alpha$  complexes (green). Overview (upper row): Arrows indicate T cells, arrow heads highlight a cytoplasm bridge of a WT DCs. Scale bar = 10  $\mu$ m. Confocal images of individual DC-T cell (arrow heads) interactions. Middle row (xy plain) and lower row (xz plain): Scale bar = 5  $\mu$ m. Representative of two experiments. (c) Quantification of IL-6-IL-6R $\alpha$  complexes (PLA signals) per DC. Mean + SD, \*P<0.0001, ANOVA plus Tukey post test.



### Figure 6. IL-6 cluster signaling is operational *in vivo*.

(a) *Ex vivo* flow cytometric assessment of surface expression of the IL-6R subunits IL-6Rα and gp130 in CD11c<sup>+</sup>MHC class II<sup>high</sup> CD11b<sup>+</sup>DCs isolated from the dLN of MOG<sub>35-55</sub> immunized WT mice on day 10. Representative cytograms out of two experiments. (b) CD11c Cre x *Il6*<sup>RD/wt</sup> x R26 *Stop*<sup>flox/flox</sup> YFP mice were treated with Flt3L cells as described in Supplementary Fig. 2. Two days after LPS injection, LN cells were prepared and stained *ex vivo*. Surface IL-6Rα expression is depicted in IL-6 (Thy1.1)<sup>-</sup> vs IL-6 (Thy1.1)<sup>+</sup> CD11b<sup>+</sup> DCs (Numbers in histogram plots depict MFI). (c) Mean clinical EAE

scores of *Il6ra<sup>flox/flox</sup>* control and *Il6ra<sup>ADC</sup>* mice + SEM, n  $\geq$  4. \*P<0.05, ANOVA plus Sidak post test. Representative of four experiments. (d) Naive T cells (CD4<sup>+</sup>CD44<sup>-</sup>GFP (Foxp3)<sup>-</sup>; left column) from 2D2 x *Foxp3<sup>gfp</sup>*.KI mice were transferred into WT congenic (CD45.1) mice followed by MOG<sub>35-55</sub> immunization. At the indicated time points, 2D2 T cells were re-isolated from dLN and surface IL-6R $\alpha$  expression was measured in activated (CD69<sup>+</sup> or CD25<sup>+</sup>) effector (GFP (Foxp3)<sup>-</sup>) 2D2 T cells vs non-activated 2D2 T cells (black). (e) Frequencies of Foxp3<sup>+</sup> Tregs in dLN CD4<sup>+</sup> T cells of control mice (*Il6ra<sup>flox/flox</sup>*) vs *Il6ra<sup>ADC</sup>*, and *Il6ra<sup>AT</sup>* animals. Mean + SD, n  $\geq$  4, \*P<0.003 (ANOVA plus Tukey's multiple comparisons test). (f) Course of EAE in *Il6ra<sup>flox/flox</sup>* control mice vs isotype treated and Treg-depleted *Il6ra<sup>AT</sup>* mice. To deplete Tregs, 0.5 mg of anti-CD25 (PC61) were injected *i.p.* on days -5 and -3 prior to immunization. Mean EAE scores + SEM, n  $\geq$  9. \*P<0.05, ANOVA plus Sidak post test.




**Figure 7. T cell priming is aberrant in an *Il6 $\Delta$ DC* environment and results in non-pathogenic T cells.**

CD4<sup>+</sup>Foxp3<sup>-</sup> effector T cells were purified from dLN of MOG<sub>35-55</sub> immunized control (*Il6<sup>flox/flox</sup>*), *Il6<sup>-/-</sup>*, or *Il6 $\Delta$ DC* mice and analyzed by nanostring. (a) GSEA for a non-pathogenic T<sub>H</sub>17 gene set 8 was performed. *Il6st* (encoding gp130), *Eomes*, and *Cd96* were highly enriched in effector T cells primed in *Il6 $\Delta$ DC* mice. (b, c) Control mice or *Il6 $\Delta$ DC* mice were immunized with MOG<sub>35-55</sub> and after 7 days, the expression of CD96 (b) and intracellular cytokines (c) were assessed on CD40L<sup>+</sup> T cells upon restimulation with

MOG<sub>35-55</sub>. Representative of two experiments, mean + SD, n=4, **(b)** \*P=0.0066, unpaired t-test; **(c)** \*P <0.005, ANOVA plus Sidak's multiple comparisons test. **(d)** Naïve WT or IL-6R $\alpha$  deficient T cells were stimulated in the presence of TGF- $\beta$  (0.1 ng/ml) and either IL-6 or hyper-IL-6 followed by assessment of CD96 expression. Representative of two experiments. **(e, f)** Naïve WT T cells were activated in the presence of TGF- $\beta$  and equimolar concentrations of either soluble IL-6 or hyper-IL-6. Subsequent to PMA/ionomycin restimulation, cells were stained for IL-17 and IFN- $\gamma$  **(e)**. Representative of three experiments, mean + SD, n=2, \*P<0.04, ANOVA plus Holm-Sidak post test. *Rorc*, *Tbx21* and *Eomes* mRNA expression was analyzed **(f)**. Mean + SD of technical replicates. Representative of of two experiments. \*P<0.04, ANOVA plus Holm-Sidak post test. **(g, h)** Naïve T cells from GFP (IL-23R) reporter mice were stimulated in the presence of TGF- $\beta$  plus equimolar concentrations of IL-6 or hyper-IL-6. After 2 days, GFP (IL-23R) expression was measured **(g)**. Mean + SD, n=3. \*P<0.03, ANOVA plus Holm-Sidak post test. Representative of two experiments **(h)**.





**Figure 8. Aberrant priming of TH17 cells in the absence of DC mediated IL-6 cluster signaling is reversed by neutralization of IFN- $\gamma$  in vivo.**

(a, b) Naive 2D2 T cells were labeled with a proliferation dye and transferred into either *Il6<sup>flox/flox</sup>* control mice or *Il6<sup>ADC</sup>* animals followed by immunization with MOG<sub>35-55</sub>. After re-isolation on day 7 after immunization, proliferation and intracellular cytokines were assessed in 2D2 T cells. Representative of two experiments, mean + SD, n=4. \*P<0.04, t-test. (c) The disease phenotype of *Il6<sup>ADC</sup>* mice is rescued upon neutralization of IFN- $\gamma$ . Control mice (*Il6<sup>flox/flox</sup>*) or *Il6<sup>ADC</sup>* mice were immunized with MOG<sub>35-55</sub> and either control

treated (rat IgG1) or injected i.p. with 200  $\mu$ g anti-IFN- $\gamma$  every other day until day 11 after immunization. Representative of two experiments. Mean EAE scores + SEM, n=4 per group, \*P<0.05, ANOVA plus Tukey post test.